A phase 2 study of ruxolitinib, an oral JAK1 and JAK2...

Cancer 2014 / 02 Vol. 120; Iss. 4

A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea

Verstovsek, Srdan, Passamonti, Francesco, Rambaldi, Alessandro, Barosi, Giovanni, Rosen, Peter J., Rumi, Elisa, Gattoni, Elisabetta, Pieri, Lisa, Guglielmelli, Paola, Elena, Chiara, He, Shui, Contel,
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
120
Language:
english
Journal:
Cancer
DOI:
10.1002/cncr.28441
Date:
February, 2014
File:
PDF, 341 KB
english, 2014
Conversion to is in progress
Conversion to is failed